HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity

Journal of Dermatological Science

Volumn 55, Issue 2, 2009, Pages 116-122

  Yin, Rui ^a   Zheng, Wenjie ^a   Hao, Fei ^a   Yang, Xi Chuan ^a   Zhong, Bai Yu ^a   Li, Qin Jie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Condyloma acuminatum; CTL; DC; HPV16; Immunotherapy; KDEL sequence

Indexed keywords

CANCER VACCINE; CHROMIUM 51; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; LYSYLASPARTYLGLUTAMYLLEUCINE; PEPTIDE; PROTEIN E7; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SOLID PHASE SYNTHESIS; SPLEEN CELL; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

ANIMALS; CANCER VACCINES; CELL LINE, TRANSFORMED; DENDRITIC CELLS; DRUG DESIGN; FEMALE; HLA-A2 ANTIGEN; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; PROTEIN SORTING SIGNALS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TIME FACTORS;

EID: 67649668913     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2009.04.008     Document Type: Article

References (37)

1. Stanley M. The epidemiology and burden of HPV disease. Nurs Times 104 (2008) 38-40
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
3. Pagliusi S.R., and Aguado M.T. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23 (2004) 569-578
4. Bosch F.X. A scientific response to prevent cervical cancer in the world. Vaccine 19 26 Suppl 12 (2008) v-vi
5. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulse dendritic cells. Nat Med 4 (1998) 328-332
6. Thurner B., Haendle I., Röder C., Dieckmann D., Keikavoussi P., Jonuleit H., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190 (1999) 1669-1678
7. Bellone M., Cantarella D., Castiglioni P., Crosti M.C., Ronchetti A., Moro M., et al. Relevance of the tumor antigen in the validation of three vaccination strategies for malnoma. J Immunol 165 (2000) 2626-2651
8. Schreurs M.W., Eggert A.A., de Boer A.J., Vissers J.L., van Hall T., Offringa R., et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60 (2000) 6995-7001
9. Dallal R.M., and Lotze M.T. The dendritic cell and human cancer vaccine. Curr Opin Immunol 12 (2000) 583-588
10. Bullock T.N., Colella T.A., and Engelhard V.H. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J Immunol 164 (2000) 2354-2361
11. Ludewig B., Odermatt B., Ochsenbein A.F., Zinkernagel R.M., and Hengartner H. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev 169 (1999) 45-54
12. Slansky J.E., Rattis F.M., Boyd L.F., Fahmy T., Jaffee E.M., Schneck J.P., et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13 (2000) 529-538
13. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157 (1996) 2539-2548
14. Valmori D., Fonteneau J.F., Lizana C.M., Gervois N., Lienard D., Rimoldi D., et al. Enhanced generation of specific tumorreactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160 (1998) 1750-1758
15. Wang H.Y., Fu T., Wang G., Zeng G., Perry-Lally D.M., Yang J.C., et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 109 (2002) 1463-1470
16. Wang R.F., and Wang H.Y. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 20 (2002) 149-154
17. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 1 (1996) 21-26
18. Steinman R.M., and Witmer M.D. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 75 (1978) 5132-5136
19. Boon T., Van Snick J., Van Pel A., Uyttenhove C., and Marchand M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med 152 (1980) 1184-1193
20. Wang L., Wu Y.Z., Chen A., Zhang J.B., Yang Z., Niu W., et al. MHC class I associated presentation of exogenous peptides is not only enhanced but also prolonged by linking with a C-terminal Lys-Asp-Glu-Leu endoplasmic reticulum retrieval signal. Eur J Immunol 34 (2004) 3582-3594
21. Doan T., Chambers M., Street M., Fernando G.J., Herd K., Lambert P., et al. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology 244 (1998) 352-364
22. Anderson S., Mints M., Sällströn J., and Wilander E. The relative distribution of oncogneic types of human papillomavirus in benign, pre-malignant and malignant cervical biopsies. A study with human papillomavirus deoxyribonucleic acid sequence analysis. Cancer Detect Prev 29 (2005) 37-41
23. Stanley M. Immune responses to human papillomavirus. Vaccine 24 Suppl 1 (2006) S16-S22
24. Scholten K.B., Schreurs M.W., Ruizendaal J.J., Kueter E.W., Kramer D., Veenbergen S., et al. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol 114 (2005) 119-129
25. Ressing M.E., Stte A., Brandt R.M., Ruppert J., Wentworth P.A., and Hartman M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154 (1995) 5934-5943
26. Sidney J., Grey H.M., Kubo R.T., and Sette A. Practical, biochemical and evolutionary implications of HLA class I supermotifs. Immnol Today 17 (1996) 261-266
27. Eiben G.L., Velders M.P., Schreiber H., Cassetti M.C., Pullen J.K., Smith L.R., et al. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficiency of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 62 (2002) 5792-5799
28. Davidson E.J., Kitchener H.C., and Stern P.L. The use of vaccines in the prevention and treatment of cervical cancer. Clin Oncol 14 (2002) 193-200
29. Pap E.H., Dansen T.B., van Summeren R., and Wirtz K.W. Peptide-based targeting of fluorophores to organelles in living cells. Exp Cell Res 265 (2001) 288-293
30. Pichon C., Arar K., Stewart A.J., Dodon M.D., Gazzolo L., Courtoy P.J., et al. Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif. Mol Pharmacol 51 (1997) 431-438
31. Johannes L., Tenza D., Antony C., and Goud B. Retrograde transport of KDEL-bearing B-fragment of Shiga toxin. J Biol Chem 272 (1997) 19554-19561
32. Griffiths G., Ericsson M., Krijnse-Locker J., Nilsson T., Goud B., Soling H.D., et al. Localization of the Lys, Asp, Glu, Leu tetrapeptide receptor to the Golgi complex and the intermediate compartment in mammalian cells. J Cell Biol 127 (1994) 1557-1574
33. Day P.M., Yewdell J.W., Porgador A., Germain R.N., and Bennink J.R. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc Natl Acad Sci USA 94 (1997) 8064-8069
34. Luft T., Rizkalla M., Tai T.Y., Chen Q., MacFarlan R.I., Davis I.D., et al. Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation. J Immunol 167 (2001) 2529-2537
35. Levitt J.M., Howell D.D., Rodgers J.R., and Rich R.R. Exogenous peptides enter the endoplasmic reticulum of TAP deficient cells and induce the maturation of nascent MHC class I molecules. Eur J Immunol 31 (2001) 1181-1190
36. Townsend A., Ohlen C., Bastin J., Ljunggren H.G., Foster L., and Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340 (1989) 443-448
37. + CTL is more efficient than exogenous presentation. Immunol Cell Biol 74 (1996) 394-400